secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041275
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023
-----------------------------------------------------------------

- Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.
- Cash and investments $142.7M as of June 30; raised $68.3M gross in May offering.
- Topline data from pivotal mavodelpar STRIDE study in PMM due in Q4 2023.
- Over 130 patients enrolled in STRIDE AHEAD OLE study; criteria expanded to nDNA defects.
- R&D expenses $14.4M (up from $8.1M) driven by clinical and manufacturing costs for mavodelpar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/0000950170-23-041275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023041275/rphm-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer